Posts

Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy

Authors: Mathieu Kuchenbuch, Gianluca D’Onofrio, Nicole Chemaly, Giulia Barcia, Théo Teng, Rima Nabbout Published in Epilepsia Open July 2020 Abstract Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug-resistant in this syndrome with frequent drop attacks. In a prospective study of add-on cannabidiol (CBD), we identified…

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Cannabinoids in treatment-resistant epilepsy: A review.

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

Authors: Evan J. Hess, Kirsten A. Moody, Alexandra L. Geffrey, Sarah F. Pollack, et al
Epilepsia, October 2016

OBJECTIVE: Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment-resistant epilepsy. He…

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016

BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…

Cannabinoids and Epilepsy.

Authors: Evan C. Rosenberg, Richard W. Tsien, Benjamin J. Whalley, Orrin Devinsky
Neurotherapeutics, October 2015

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid syst…

Marijuana Use in Epilepsy: The Myth and the Reality.

Authors: Kamil Detyniecki, Lawrence Hirsch
Current Neurology and Neuroscience Reports, October 2015

Marijuana has been utilized as a medicinal plant to treat a variety of conditions for nearly five millennia. Over the past few years, there has been an unprecedented interest in using cannabis extracts to treat epilepsy, spurred on by a few refractory pediatric cases featured…

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015

BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…

Phytocannabinoids and epilepsy.

Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015

WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.

Authors: Magdalena Florek-Luszczki, Aleksandra Wlaz, Maria W. Kondrat-Wrobel, et al
Journal of Neural Transmission, July 2014

The aim of this study was to characterize the influence of WIN 55,212-2 (WIN–a non-selective cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant effects of various classical antiepileptic drugs (clobazam, clonazepam, phenobarbital and valproate) in the mouse 6 Hz-…

The case for medical marijuana in epilepsy.

Authors: Edward Maa, Paige Figi
Epilepsia, June 2014

Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive thera…